IGC Pharma annual working capital
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma Working Capital Growth & History (IGC)
IGC Pharma's working capital was −$366,000 for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | −$366,000 | — | — |
| 2025 · Mar 31 | 2025-03-31 | $639,000 | −$726,000 | −53.19% |
| 2024 | 2024-03-31 | $1.4M | −$3.2M | −70.12% |
| 2023 | 2023-03-31 | $4.6M | −$8.1M | −63.95% |
| 2022 | 2022-03-31 | $12.7M | −$8.5M | −40.09% |
| 2021 | 2021-03-31 | $21.1M | $5.3M | +33.76% |
| 2020 | 2020-03-31 | $15.8M | −$10.0M | −38.82% |
| 2019 | 2019-03-31 | $25.8M | $25.0M | +2908.73% |
| 2018 | 2018-03-31 | $859,000 | −$1.4M | −62.52% |
| 2017 | 2017-03-31 | $2.3M | $1.6M | +256.46% |
| 2016 | 2016-03-31 | $642,888 | −$1.4M | −68.33% |
| 2015 | 2015-03-31 | $2.0M | −$697,930 | −25.59% |
| 2014 | 2014-03-31 | $2.7M | $284,108 | +11.63% |
| 2013 | 2013-03-31 | $2.4M | $1.7M | +237.41% |
| 2012 | 2012-03-31 | $724,243 | $756,426 | — |
| 2011 | 2011-03-31 | −$32,183 | — | — |
IGC Pharma quarterly working capital
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | −$2.0M | −$2.4M | — |
| Q1 2026 · Mar 31 | 2026-03-31 | −$1.7M | −$2.4M | — |
| Q4 2025 · Dec 31 | 2025-12-31 | −$366,000 | −$760,000 | — |
| Q2 2026 · Sep 30 | 2025-09-30 | $490,000 | −$958,000 | −66.16% |
| Q1 2026 · Jun 30 | 2025-06-30 | $428,000 | −$1.5M | −77.69% |
| Q4 2025 · Mar 31 | 2025-03-31 | $639,000 | −$726,000 | −53.19% |
| Q3 2025 | 2024-12-31 | $394,000 | −$1.3M | −76.08% |
| Q2 2025 | 2024-09-30 | $1.4M | −$2.6M | −63.90% |
| Q1 2025 | 2024-06-30 | $1.9M | −$1.0M | −34.92% |
| Q4 2024 | 2024-03-31 | $1.4M | −$3.2M | −70.12% |
| Q3 2024 | 2023-12-31 | $1.6M | −$6.4M | −79.41% |
| Q2 2024 | 2023-09-30 | $4.0M | −$5.8M | −59.14% |
| Q1 2024 | 2023-06-30 | $2.9M | −$8.1M | −73.37% |
| Q4 2023 | 2023-03-31 | $4.6M | −$8.1M | −63.95% |
| Q3 2023 | 2022-12-31 | $8.0M | −$10.0M | −55.46% |
| Q2 2023 | 2022-09-30 | $9.8M | −$9.9M | −50.14% |
| Q1 2023 | 2022-06-30 | $11.1M | −$9.0M | −44.87% |
| Q4 2022 | 2022-03-31 | $12.7M | −$8.5M | −40.09% |
| Q3 2022 | 2021-12-31 | $18.0M | $8.5M | +88.97% |
| Q2 2022 | 2021-09-30 | $19.7M | $7.9M | +67.01% |
| Q1 2022 | 2021-06-30 | $20.1M | $6.4M | +46.74% |
| Q4 2021 | 2021-03-31 | $21.1M | $5.3M | +33.76% |
| Q3 2021 | 2020-12-31 | $9.5M | −$9.7M | −50.52% |
| Q2 2021 | 2020-09-30 | $11.8M | −$10.5M | −47.06% |
| Q1 2021 | 2020-06-30 | $13.7M | −$9.8M | −41.78% |
| Q4 2020 | 2020-03-31 | $15.8M | −$10.0M | −38.82% |
| Q3 2020 | 2019-12-31 | $19.2M | −$8.4M | −30.48% |
| Q2 2020 | 2019-09-30 | $22.3M | $17.0M | +325.24% |
| Q1 2020 | 2019-06-30 | $23.5M | $23.0M | +5005.43% |
| Q4 2019 | 2019-03-31 | $25.8M | $25.0M | +2908.73% |
| Q3 2019 | 2018-12-31 | $27.6M | $25.7M | +1352.76% |
| Q2 2019 | 2018-09-30 | $5.2M | $4.4M | +551.56% |
| Q1 2019 | 2018-06-30 | $460,373 | −$163,611 | −26.22% |
| Q4 2018 | 2018-03-31 | $859,000 | −$1.4M | −62.52% |
| Q3 2018 | 2017-12-31 | $1.9M | $825,623 | +76.73% |
| Q2 2018 | 2017-09-30 | $803,769 | $743,533 | +1234.37% |
| Q1 2018 | 2017-06-30 | $623,984 | $516,388 | +479.93% |
| Q4 2017 | 2017-03-31 | $2.3M | $1.6M | +256.46% |
| Q3 2017 | 2016-12-31 | $1.1M | −$1.1M | −50.20% |
| Q2 2017 | 2016-09-30 | $60,236 | −$2.2M | −97.34% |
| Q1 2017 | 2016-06-30 | $107,596 | −$2.2M | −95.26% |
| Q4 2016 | 2016-03-31 | $642,888 | −$1.4M | −68.33% |
| Q3 2016 | 2015-12-31 | $2.2M | −$616,281 | −22.19% |
| Q2 2016 | 2015-09-30 | $2.3M | −$888,373 | −28.20% |
| Q1 2016 | 2015-06-30 | $2.3M | −$2.2M | −49.18% |
| Q4 2015 | 2015-03-31 | $2.0M | −$697,930 | −25.59% |
| Q3 2015 | 2014-12-31 | $2.8M | $2.2M | +405.71% |
| Q2 2015 | 2014-09-30 | $3.2M | $2.7M | +633.65% |
| Q1 2015 | 2014-06-30 | $4.5M | $2.4M | +116.14% |
| Q4 2014 | 2014-03-31 | $2.7M | $284,108 | +11.63% |
| Q3 2014 | 2013-12-31 | $549,138 | −$1.2M | −68.46% |
| Q2 2014 | 2013-09-30 | $429,434 | −$538,335 | −55.63% |
| Q1 2014 | 2013-06-30 | $2.1M | $1.6M | +340.07% |
| Q4 2013 | 2013-03-31 | $2.4M | $1.7M | +237.41% |
| Q3 2013 | 2012-12-31 | $1.7M | $130,376 | +8.09% |
| Q2 2013 | 2012-09-30 | $967,769 | $1.2M | — |
| Q1 2013 | 2012-06-30 | $469,748 | $301,882 | +179.84% |
| Q4 2012 | 2012-03-31 | $724,243 | $756,426 | — |
| Q3 2012 | 2011-12-31 | $1.6M | — | — |
| Q2 2012 | 2011-09-30 | −$204,946 | — | — |
| Q1 2012 | 2011-06-30 | $167,866 | — | — |
| Q4 2011 | 2011-03-31 | −$32,183 | — | — |
IGC Pharma working capital trends
Between the periods ended 2011-03-31 and 2025-12-31, IGC Pharma's working capital decreased from −$32,183 to −$366,000, a change of −$333,817. The latest reported quarter, Q2 2026 · Jun 30, shows −$2.0M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗